Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

Franck Emmanuel Nicolini, Grzegorz W. Basak, Simona Soverini, Giovanni Martinelli, Michael J. Mauro, Martin C. Müller, Andreas Hochhaus, Charles Chuah, Inge H. Dufva, Giovanna Rege-Cambrin, Giuseppe Saglio, Mauricette Michallet, Hélène Labussière, Stéphane Morisset, Sandrine Hayette, Gabriel Etienne, Eduardo Olavarria, Wei Zhou, Senaka Peter, Jane F. ApperleyJorge Cortes

Research output: Contribution to journalArticle

Abstract

T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)5697-5700
Number of pages4
JournalBlood
Volume118
Issue number20
DOIs
StatePublished - Nov 17 2011
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Stem cells
Leukemia
Transplantation
Chromosomes
Blast Crisis
Philadelphia Chromosome
Protein-Tyrosine Kinases
Hazards
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation
Leukemia, Myeloid, Accelerated Phase
Transplants
Leukemia, Myeloid, Chronic Phase
Survival
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stem Cells
Multivariate Analysis
Tissue Donors
Mortality

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nicolini, F. E., Basak, G. W., Soverini, S., Martinelli, G., Mauro, M. J., Müller, M. C., ... Cortes, J. (2011). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood, 118(20), 5697-5700. https://doi.org/10.1182/blood-2011-07-367326

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. / Nicolini, Franck Emmanuel; Basak, Grzegorz W.; Soverini, Simona; Martinelli, Giovanni; Mauro, Michael J.; Müller, Martin C.; Hochhaus, Andreas; Chuah, Charles; Dufva, Inge H.; Rege-Cambrin, Giovanna; Saglio, Giuseppe; Michallet, Mauricette; Labussière, Hélène; Morisset, Stéphane; Hayette, Sandrine; Etienne, Gabriel; Olavarria, Eduardo; Zhou, Wei; Peter, Senaka; Apperley, Jane F.; Cortes, Jorge.

In: Blood, Vol. 118, No. 20, 17.11.2011, p. 5697-5700.

Research output: Contribution to journalArticle

Nicolini, FE, Basak, GW, Soverini, S, Martinelli, G, Mauro, MJ, Müller, MC, Hochhaus, A, Chuah, C, Dufva, IH, Rege-Cambrin, G, Saglio, G, Michallet, M, Labussière, H, Morisset, S, Hayette, S, Etienne, G, Olavarria, E, Zhou, W, Peter, S, Apperley, JF & Cortes, J 2011, 'Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias', Blood, vol. 118, no. 20, pp. 5697-5700. https://doi.org/10.1182/blood-2011-07-367326
Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Nov 17;118(20):5697-5700. https://doi.org/10.1182/blood-2011-07-367326
Nicolini, Franck Emmanuel ; Basak, Grzegorz W. ; Soverini, Simona ; Martinelli, Giovanni ; Mauro, Michael J. ; Müller, Martin C. ; Hochhaus, Andreas ; Chuah, Charles ; Dufva, Inge H. ; Rege-Cambrin, Giovanna ; Saglio, Giuseppe ; Michallet, Mauricette ; Labussière, Hélène ; Morisset, Stéphane ; Hayette, Sandrine ; Etienne, Gabriel ; Olavarria, Eduardo ; Zhou, Wei ; Peter, Senaka ; Apperley, Jane F. ; Cortes, Jorge. / Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. In: Blood. 2011 ; Vol. 118, No. 20. pp. 5697-5700.
@article{7f4548ea387d4f88ae7c0e7e67a045c8,
title = "Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias",
abstract = "T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5{\%} of patients with chronic myeloid leukemia were in the chronic phase and 4.5{\%} were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.",
author = "Nicolini, {Franck Emmanuel} and Basak, {Grzegorz W.} and Simona Soverini and Giovanni Martinelli and Mauro, {Michael J.} and M{\"u}ller, {Martin C.} and Andreas Hochhaus and Charles Chuah and Dufva, {Inge H.} and Giovanna Rege-Cambrin and Giuseppe Saglio and Mauricette Michallet and H{\'e}l{\`e}ne Labussi{\`e}re and St{\'e}phane Morisset and Sandrine Hayette and Gabriel Etienne and Eduardo Olavarria and Wei Zhou and Senaka Peter and Apperley, {Jane F.} and Jorge Cortes",
year = "2011",
month = "11",
day = "17",
doi = "10.1182/blood-2011-07-367326",
language = "English (US)",
volume = "118",
pages = "5697--5700",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

AU - Nicolini, Franck Emmanuel

AU - Basak, Grzegorz W.

AU - Soverini, Simona

AU - Martinelli, Giovanni

AU - Mauro, Michael J.

AU - Müller, Martin C.

AU - Hochhaus, Andreas

AU - Chuah, Charles

AU - Dufva, Inge H.

AU - Rege-Cambrin, Giovanna

AU - Saglio, Giuseppe

AU - Michallet, Mauricette

AU - Labussière, Hélène

AU - Morisset, Stéphane

AU - Hayette, Sandrine

AU - Etienne, Gabriel

AU - Olavarria, Eduardo

AU - Zhou, Wei

AU - Peter, Senaka

AU - Apperley, Jane F.

AU - Cortes, Jorge

PY - 2011/11/17

Y1 - 2011/11/17

N2 - T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.

AB - T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=80755185510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755185510&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-07-367326

DO - 10.1182/blood-2011-07-367326

M3 - Article

C2 - 21926354

AN - SCOPUS:80755185510

VL - 118

SP - 5697

EP - 5700

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -